Drugs / RDX-002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05857566 | May → Jul 2023 | — | Response Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06640972 | Sep 2024 → Jan 2025 | hyperlipoproteinemia, hypertriglyceridemia | Response Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RDX-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05857566 ↗ |
| Action | Inhibit | “A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.” NCT05857566 ↗ |
| Route | Oral | “50 mg oral tablet; 200 mg BID for 7 days” NCT05857566 ↗ |